Saudi Arabia attracts $14.9 billion investments in AI as LEAP25 kicks off in Riyadh    Arab, Islamic world slams Netanyahu's remarks against Saudi Arabia, calling it unacceptable and irresponsible    Saudi Crown Prince and IOC President discuss aspects of enhancing cooperation    Saudi, Argentinean foreign ministers discuss regional developments    Saudi, Ukrainian FMs discuss Ukrainian-Russian crisis in phone call    CyberArrow grows regional presence by expanding operations in Saudi Arabia    How amana helps traders and investors in MENA build wealth    Cold weather continues hitting most Saudi regions as Turaif records lowest temperature with minus 2°C    Israeli army withdraws from Netzarim Corridor as part of ceasefire deal with Hamas    Trump claims talks with Putin on ending Russia-Ukraine war, Kremlin remains silent    Lebanese President affirms new government is non-partisan, focused on national interest    Trump rules out deporting Prince Harry, cites marital troubles as reason for leniency    Sharifa Al-Sudairi makes historic debut at Asian Winter Games    Jaecoo J8 launches in Saudi Arabia, marking a new milestone in the Middle Eastern off-road market    Al Nassr reclaims third place with 3-0 victory over Al Fayha as Jhon Durán shines    Ivan Toney's brace secures Al Ahli victory over Al Fateh in Saudi Pro League    Karim Benzema's last-gasp winner sends Al Ittihad to the top of Roshn Saudi League French striker seals dramatic 2-1 victory over Al Taawoun with stoppage-time strike    Salvador Dalí art comes to India for the first time    GEA hosts mass wedding of 300 couples at "Night of a Lifetime" celebration during Riyadh Season 300 cars and housing as gifts for the newlyweds    Food Culture Festival kicks off in Riyadh's Diplomatic Quarter    Bollywood star Saif Ali Khan 'out of danger' after attack at home in Mumbai    Order vs. Morality: Lessons from New York's 1977 Blackout    India puts blockbuster Pakistani film on hold    The Vikings and the Islamic world    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



MSD obtains FDA's nod for its lung cancer drug
Published in The Saudi Gazette on 23 - 12 - 2015

MSD (Merck Sharp & Dohme) – a global healthcare leader, revealed recently that the US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) monotherapy, the company's anti-PD-1 (programmed death receptor-1) therapy, at a dose of 2 mg/kg every three weeks, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy.
Keytruda is the first and only anti-PD-1 therapy approved for both squamous and non-squamous metastatic NSCLC. In addition to approving Keytruda for NSCLC, FDA approved the first companion diagnostic that will enable physicians to determine the level of PD-L1 expression in a patient's tumor. However, immune-mediated adverse reactions occurred with Keytruda including pneumonitis, colitis, hepatitis, hypophysitis, hyperthyroidism, hypothyroidism, type 1 diabetes mellitus, and nephritis. The most common adverse reactions (reported in at least 20% of study patients) were fatigue (44%), cough (29%), decreased appetite (25%), and dyspnea (23%).
Based on its mechanism of action, Keytruda can cause fetal harm when administered to a pregnant woman. Female patients of reproductive potential should be advised of the potential hazard to a fetus.
The "approval of Keytruda is the result of our deep commitment to bring the benefits of immunotherapy to cancer patients," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. "Together with scientists and physicians around the world, we endeavor to improve the lives of patients suffering from these grievous illnesses."
"This important news means that we now have a new immunotherapy option to help patients with squamous and non-squamous metastatic non-small cell lung cancer with disease progression on or after platinum-containing chemotherapy and whose tumors express PD-L1," said Dr. Naiyer Rizvi, director of thoracic oncology and director of immunotherapeutics, New York Presbyterian Hospital, Columbia University Medical Center, and a principal investigator for the Keytruda lung cancer clinical program.


Clic here to read the story from its source.